Typical vial
10 mg
Common dose
2.5 mg
Frequency
1×/week
Half-life
5d
Calculate Tirzepatide reconstitution
Open the free calculator pre-filled with Tirzepatide values — no account needed.
Dosing & Protocol Overview
Research Notes
GLP-1/GIP agonist studied at weekly intervals; research protocols often escalate monthly.
How Reconstitution Works
Reconstitution is the process of mixing a lyophilized (freeze-dried) peptide powder with bacteriostatic water to create an injectable solution. The concentration depends on how much BAC water you add to the vial.
For a 10 mg vial of Tirzepatide, the calculator works out the mg/ml concentration based on your BAC water volume, then converts your target dose (2.5 mg) into the exact number of units to draw on an insulin syringe.
Try it now — pre-filled for TirzepatideTrack Your Tirzepatide Protocol
Once you've calculated your reconstitution, ReconDose lets you log every injection, build a dosing schedule, track side effects, and record biomarkers — all in one place. Create a free account to get started.
Research & References
The following publicly available studies are provided for research and educational purposes only. They are not medical advice. Click through to read the original publications.
Frias JP, et al. · New England Journal of Medicine · 2021
Phase 3 trial (SURPASS-2) comparing tirzepatide (5/10/15 mg) vs semaglutide (1 mg) over 40 weeks in 1,879 patients. Tirzepatide at all doses was superior to semaglutide for HbA1c reduction and weight loss. Weight reduction was 1.9–5.5 kg greater with tirzepatide. GI adverse events were primarily mild to moderate.
Garvey WT, et al. · New England Journal of Medicine (SURMOUNT-5) · 2025
72-week phase 3b trial in 751 participants with obesity but without diabetes. Tirzepatide achieved -20.2% body weight vs -13.7% with semaglutide. Tirzepatide was superior for weight reduction and waist circumference. GI adverse events were mostly mild to moderate during dose escalation.
Rosenstock J, et al. · The Lancet · 2021· CC-BY-NC
40-week double-blind phase 3 trial in 478 patients with type 2 diabetes. All tirzepatide doses (5/10/15 mg) were superior to placebo for HbA1c reduction, fasting glucose, and body weight. Established tirzepatide as an effective dual GIP/GLP-1 receptor agonist.
Have a study we should add? Let us know. See our research hub for more studies and the Khavinson peptide bioregulator collection.